ESMO 2021: KEYNOTE-716 Study
Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 study
Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 study
Highlights on combination of pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: The KEYNOTE-355 study
In what has been described as a paradigm shift in the treatment of melanoma, drug…
The Oncology Journal Club Episode 47: Fake Cancer News and Conflicts of Interest This week…
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a…
Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type…
Increasing neoadjuvant pembrolizumab from one to two cycles prior to surgery improved pathological response rates…
Was Beethoven’s death-the result of medical malpractice? This week the OJC team tackle this crucial…
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Modern immunotherapeutic anti-cancer drugs support a natural mechanism of the immune system to inhibit the…